Reuters logo
BRIEF-Imbruvica Plus Rituximab Phase 3 Innovate Trial In Rare Waldenström's Macroglobulinemia Met Primary Endpoint
December 5, 2017 / 1:46 PM / 12 days ago

BRIEF-Imbruvica Plus Rituximab Phase 3 Innovate Trial In Rare Waldenström's Macroglobulinemia Met Primary Endpoint

Dec 5 (Reuters) - Abbvie Inc:

* IMBRUVICA® (IBRUTINIB) PLUS RITUXIMAB PHASE 3 INNOVATE TRIAL IN RARE WALDENSTRÖM‘S MACROGLOBULINEMIA MET PRIMARY ENDPOINT

* ABBVIE - PHARMACYCLICS, JANSSEN PLAN TO SHARE INTERIM ANALYSIS DATA FROM PHASE 3 INNOVATE STUDY WITH REGULATORY AUTHORITIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below